Digitalis Glycosides Reduce Heart Failure Events

What Are Digitalis Glycosides and Why Are They Being Reconsidered?

Digitalis glycosides, including digoxin and digitoxin, are among the oldest pharmacological treatments in cardiology, originally derived from the foxglove plant (Digitalis purpurea) and described clinically by William Withering in 1785. The drugs work by inhibiting the sodium-potassium ATPase pump in cardiac muscle cells, which indirectly increases intracellular calcium and strengthens myocardial contraction. They also modulate the autonomic nervous system, reducing sympathetic activity and slowing atrial conduction.

Although digoxin was a mainstay of heart failure therapy for decades, its use declined sharply following neutral mortality results in the landmark DIG trial published in The New England Journal of Medicine in 1997, and the subsequent rise of beta-blockers, ACE inhibitors, ARNIs, and SGLT2 inhibitors. The new analyses presented at Heart Failure 2026 suggest that, when used appropriately in selected patients, digitalis may still reduce hospitalizations and improve symptom control — a finding that could reshape its role in contemporary guideline-directed medical therapy.

How Could Digitalis Fit Into Modern Heart Failure Treatment?

Modern heart failure management is built on the four pillars of guideline-directed medical therapy recommended by the European Society of Cardiology and the American College of Cardiology: ARNIs or ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Despite this aggressive multi-drug approach, many patients remain symptomatic, and heart failure hospitalizations continue to drive substantial morbidity and healthcare costs.

The new analyses suggest digitalis glycosides could offer benefit as add-on therapy, particularly in patients with concurrent atrial fibrillation where rate control is needed, or in those who remain symptomatic despite optimized four-pillar therapy. Clinical use requires careful attention to therapeutic drug monitoring, given digoxin's narrow therapeutic index and the risk of toxicity in patients with renal impairment, electrolyte abnormalities, or drug interactions. The renewed evidence base will likely prompt updated discussions in upcoming ESC and AHA heart failure guidelines.

What Are the Safety Considerations With Digitalis Therapy?

Digitalis toxicity remains a real clinical concern. Symptoms can include nausea, vomiting, visual disturbances (classically yellow-green halos), confusion, and dangerous arrhythmias including ventricular tachycardia and high-grade AV block. Risk factors for toxicity include impaired renal clearance, hypokalemia, hypomagnesemia, hypercalcemia, advanced age, and interactions with drugs such as amiodarone, verapamil, and certain antibiotics.

Contemporary practice favors lower target serum digoxin concentrations (typically 0.5 to 0.9 ng/mL) than were used historically, based on post-hoc analyses of the DIG trial suggesting better outcomes at lower levels. The Heart Failure Association recommends periodic monitoring of digoxin levels, renal function, and serum potassium. For severe toxicity, digoxin-specific antibody fragments (DigiFab) provide an effective antidote.